Compare CVS Health Corp (CVS) vs BlackRock TCP Capital Corp (TCPC) Price & Performance

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

TCPC trades at $4.11, up 5.38% in 24 hours, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported Q2 2026 earnings of $0.22 per share, beating expectations, and announced a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a net income margin of 118.75% reflecting significant losses relative to revenue.

The outlook is mixed: strategic actions like portfolio sales and dividend payments ($0.17 per share) support value, but persistent losses and class action lawsuits pose risks. Analyst consensus leans hold, with 30.77% buy ratings, indicating cautious optimism amid financial challenges.